Summary Nasopharyngeal carcinoma is a subset of head and neck squamous cell cancers with unique endemic distribution and aetiological co-factors. Epstein-Barr virus has been revealed to be an important aetiological factor for most nasopharyngeal carcinomas. Nevertheless, additional genetic alterations may be involved in their development and progression. The aim of this study was to determine the likely chromosomal locations of tumour-suppressor genes related to Epstein-Barr virus-associated nasopharyngeal carcinoma. Fifty-six microsatellite polymorphic markers located on every autosomal arm were used to estimate the incidence of loss of heterozygosity in 27 Epstein-Barr virus-associated nasopharyngeal carcinomas. High frequencies of allelic loss were observed on chromosome 3p (75.0%) and 9p (87.0%). Chromosome 9q, 11q, 13q and 14q displayed loss in over 50%, while chromosome 3q, 6p, 16q, 19q and 22q exhibited loss in 35-50%. Furthermore, several other chromosomal arms demonstrated allelic loss in 20-35%. Additionally, 1 of the 27 cases showed microsatellite instability at multiple loci. These findings provide evidence of multiple genetic alterations during cancer development and clues for further studies of tumour-suppressor genes in Epstein-Barr virus-associated nasopharyngeal carcinoma.
Nasopharyngeal carcinoma (NPC) is a subset of head and neck squamous cell cancers (HNSCC) with unique endemic distribution and aetiological co-factors (Fandi et al, 1994) . Although NPC is rare among Caucasians in Europe and North America, it is one of the most common cancers in southern China and among Eskimos in Arctic regions, where it has an incidence of 20-50 per 100 000 men. An intermediate incidence is noted in South-East Asia (Voravud, 1990) . While HNSCC is closely associated with exposure to tobacco and alcohol, Epstein-Barr virus (EBV) appears to be an important aetiological factor for most NPC (Liebowitz, 1994) .
Loss of function of tumour-suppressor genes has been implicated as being essential for solid tumour development and related to chromosomal rearrangement regarding the loss of normal chromosomes or segments (Knudson, 1971; Zhu et al, 1992) . Various studies in NPC reported frequent allelic loss on chromosome 3p, 9p and llq and homozygous deletion or hypermethylation of the p16 gene (Huang et al, 1991; Choi et al, 1993; Lo et al, 1995 -1996 , Hui et al, 1996 . The aim of this study was to investigate whether other tumour-suppressor genes are also involved in NPC development by analysing the loss of heterozygosity (LOH) on every autosomal arm. Interestingly, allelotyping of HNSCC have been well characterized (Nawroz et al, 1994; El-Naggar et al, 1995; Field et al, 1995) . Allelic loss on chromosome 3p, 9p and 1 lq are also frequent events in HNSCC. In addition, frequent LOH was observed on other chromosomes, e.g. 6p, 8, 13q, 14q, 17p, 18q and 19q (Nawroz et al, 1994; El-Naggar et al, 1995; Field et al, 1995) . It would be of great interest and importance to elucidate whether the genetic events in Epstein-Barr virus-associated NPC are similar or distinct from HNSCC.
MATERIALS AND METHODS
Tissues and DNA extraction Primary NPC tissues were collected from 27 patients before treatment at Chulalongkorn University Hospital. The tissues were divided into two pieces. The first part was sent for routine histological examination. The second part was immediately stored in liquid nitrogen until further use. All the tumours were histologically ascertained to be undifferentiated NPC, according to the WHO classification. The 27 tumours included stages ranging from II to IV. Blood samples obtained by venipuncture from the same patients were used as constitutional controls. DNA was extracted from the tumour tissues and blood leucocytes by methods previously described (Maniatis et al, 1989) . EBV detection and typing by PCR For the detection and typing of EBV DNA in the tumour tissues, three previously described polymerase chain reaction (PCR) protocols were used with some modifications (Sample et al, 1990; Feinmesser et al, 1992; Lin et al, 1993) . DNA from cell line B958, EBV-transformed human lymphocytes (American TIype Culture Collection), was used as positive control and double-distilled water as negative control.
Duplex PCR was performed to detect EBV using two sets of primers. The first amplified the non-polymorphic EBV nuclear antigen 1 (EBNA-1), generating an approximately 610-bp DNA fragment. The second amplified a human ,-actin genomic sequence, generating an approximately 318-bp DNA fragment. The oligonucleotide sequences for both sets of PCR primers were identical to the ones previously reported (Feinmesser et al, 1992) .
Two sets of PCR primers were used for EBV typing. The first primer amplified the EBV nuclear antigen 2 (EBNA-2), generating a DNA fragment of 168 bp for EBV type A and of 184 bp for EBV type B. The second one amplified the EBV nuclear antigen 3C (EBNA-3C), generating a DNA fragment of 153 bp for EBV type A and of 246 bp for EBV type B. The oligonucleotide sequences for both sets of PCR primers were identical to the ones 610 previously reported (Sample et al, 1990; Lin et al, 1993) .
The PCR reactions were performed in a total volume of 20 gl 318 using 50 ng of the corresponding tumour DNA in 200 ,UM dNTP each, 1.5 mM magnesium chloride, 50 mm potassium chloride, 10 mm Tris-HCl (pH 9.0), 0.1% Triton X-100, 0.5 units of Thermus aquaticus DNA polymerase (Promega) and 0.5 gM of each primer. The PCR amplifications were performed as follows: initial denaturation at 94°C for 5 min, followed by 35 cycles of denaturation at 940C for 30 s, annealing at 57°C for 30 s, with an extension at 72'C for 1 min and a final extension at 72°C for 7 min. The PCR products were then analysed using 2% agarose gel electrophoresis. The marker sets of (D3S1600, D3S966, D9S169), (DIIS534, GABRB3, D9S51, DIOS169), (GLUT2, D2S102, TCRD), (IL2RB, D8S88), (D16S287, D4S174), (D21S258, MFD133, D20S17, DIS103), (D12S341, D19S221) and (D2S131, DlOS249) were analysed for LOH using multiplex PCR. The others were amplified as simplex PCR (Mutirangura et al, 1993) .
Several PCR reactions, indicated in parentheses in Table 1 , have been optimized for each primer set as follows: for reaction 1 and 3, the initial denaturation step at 95°C for 4 min, then followed by 25 cycles of denaturation at 94°C for 1 min, with 1 min of annealing at 55°C for reaction 1, or 52°C for reaction 3, extension at 72°C for 2 min and a final extension at 72°C for 7 min; for reaction 2, the initial denaturation step was 95°C for 4 min, then followed by Stage  III  IV  IV  IV  R  IV  II  III  IV  IV  T  3  3  2  4  4 
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LOH in NPC
A panel of 56 microsatellite polymorphic markers representing every chromosomal arm was used to screen for LOH frequency. Figure 4 . No significant clinical difference was noted regarding these cases.
DISCUSSION
Several areas of chromosomal loss during cancer development and progression are associated with inactivation of both tumoursuppressor gene alleles (Huang et al, 1991; Zhu et al, 1992; Nawroz et al, 1994) . In addition, they are correlated with the histopathology, staging and clinical outcome of cancer (Broder et al, 1995) . Here we demonstrated several chromosomes with significant LOH in NPC. While several LOH loci are common to HNSCC, some appear to be unique to NPC progression. Previously Choi et al (1993) showed LOH on chromosome 3p for all of the informative 35 NPC cases and Huang et al (1994) studied chromosome 9p and found allelic loss on 11 samples from 18 NPC. Consistently, in this study, two of the highest incidences of allelic loss have been shown on chromosomes 3p (78%) and 9p (87%). Three LOH loci have been reported on chromosomes 3p, 3pl4, 3p2l and 3p25 (Maestro et al, 1993) . This study revealed that, at least, the 3pl4 and 3p25 loci are associated with NPC development. It should also be noted that a putative tumoursuppressor gene, VHL, is the candidate gene on chromosome 3p25 (Latif et al, 1993) . For 9p, the LOH locus has been defined on chromosome band 9p21; and gene pl6, which controls cell cycles, has previously been shown to have homozygous deletion or hypermethylation (Lo et al, 1995 . Interestingly, 9p LOH has now been well documented in precancerous lesions of HNSCC (ElNaggar et al, 1995) . It is interesting to investigate whether genetic alterations of chromosome 9p might also be an early event of NPC carcinogenesis.
Allelic loss of chromosome 1 lq has been observed in several other tumour types, such as HNSCC, breast, ovary and lung (Nawroz et al, 1994; Gudmundsson et al, 1995a; lizuka et al, 1995) . Poor prognosis of breast and ovarian cancer has been associated with 1 1qLOH (Gudmundsson et al, 1995a) . At least three LOH loci have been delineated on chromosome 1lq, 1 1q13, 1 1q15 and 1 1q23 (Iizuka et al, 1995) . In addition, 1 1q13 is a chromosome region with a high frequency of amplification in HNSCC (Meredith et al, 1995) . This results in allelic imbalance and may be difficult to distinguish from LOH. This study described a higher frequency of allelic loss in NPC on 1 1q23 than on 1 1q13. It should also be noted that the LOH on 1 1q23 may be related to the ataxiatelangiectasia locus (Savitsky et al, 1995) .
Chromosome 13qLOH is also frequently detected in several cancers, such as retinoblastoma, breast cancer and HNSCC (Zhu et al, 1992; Nawroz et al, 1994; Gudmundsson et al, 1995b) . This study has shown that the common LOH locus in NPC may be located proximal to 13ql4.3. At least two tumour-suppressor genes are located proximal to this region. The first is Rb, retinoblastoma gene, and the other is BRCA2, the candidate gene for the second locus of the familial breast cancer syndrome (Zhu et al, 1992; Gudmundsson et al, 1995b) . Previous mutation analysis of Rb on NPC demonstrated negative results (Sun et al, 1993) . Thus, it is tempting to hypothesize that the BRCA2 tumoursuppressor gene may be responsible for NPC development.
The allelic loss of chromosome 14q was also frequently found in other types of cancer, e.g. bladder cancer, neuroblastoma, colorectal cancer and HNSCC (Fong et al, 1992; Young et al, 1993; Nawroz et al, 1994; Chang et al, 1995) . A recent study has delineated two tumour-suppressor gene loci on chromosome 14, i.e. 14ql2 and 14q32 (Chang et al, 1995) . Interestingly, LOH of 14q is associated with an advanced phenotype of neuroblastoma and frequently found in advanced colorectal cancer (Fong et al, 1992; Young et al, 1993) .
Chromosome 17p is one of the most common regions with genetic alterations reported in cancer. p53, the best known tumoursuppressor gene, is located on this chromosome (Carson et al, 1995) . p53 alterations, including protein expression and mutations, are common in HNSCC while mutation of p53 in NPC is infrequent (Field et al, 1991; Boyle et al, 1993; Shin et al, 1994; Brennan et al, 1995; Chakrani et al, 1995) . The LOH study of this chromosome supported the mutation data in which allelic loss of chromosome 17p was noticed in only 30% of the NPC, while previous reports revealed 50% LOH of the HNSCC (Nawroz et al, 1994; Field et al, 1995 (Thibodeau et al, 1993) . In HNPCC, mutations in a number of DNA mismatch repair genes (hMSH2, hMLH1, hPMSJ and hPMS2) have been reported. Thus, MSI may be the consequence of decreased accuracy of the DNA mismatch repair system during DNA replication, which might facilitate the accumulation of mutations (Rhyu, 1996) . This study has presented MSI of multiple loci in only one out of 27 NPC samples tested. This suggests that the phenomenon of MSI is a relatively rare event during NPC development.
NPC is a unique subclassification of HNSCC as a result of its endemic distribution and aetiological cofactors. It would be of great interest and importance to elucidate whether the genetic events in Epstein-Barr virus-associated NPC are similar or distinct from HNSCC. Previous HNSCC studies have demonstrated a high frequency of LOH on chromosomes 3p, 3q, 6p, 8p, 8q, 9p, 1 lq, 13q, 14q, 17p, 18q and 19q (Nawroz et al, 1994; El-Naggar et al, 1995; Field et al, 1995) . Nawroz et al (1994) studied 29 HNSCCs and showed 67, 50, 38, 40, 38, 72, 61, 54, 39, 52, 23 and 40% allelic losses respectively. Additionally, Field et al (1995) tested 80 specimens and found LOH more frequently on chromosome 3p, 8p, 9p, 13q, 17p, 18q and 19q for 52, 35, 62, 27, 50, 49 and 29% respectively. Finally, El-Naggar et al (1995) studied 20 patients for LOH on chromosome 3p, Sq, 8p, 9p, 9q, llq and 17p, and a high incidence of LOH in invasive carcinoma was observed at 9p (72%), 8p (53%), 3p (47%), 9q (35%) and llq (33%). Similar incidences on chromosomes 3p (78%), 3q (48%), 6p (48%), 9p (87%), llq (54%), 13q (64%) and 14q (43%) have also been detected regarding NPC. However, NPC revealed lower incidences of LOH on chromosomes 8p (13%), 17p (30%) and 19q (11%). In contrast, this study has shown frequent allelic loss regarding NPC on chromosomes 16q (48%) and 22q (46%). As several genetic alterations of NPC and HNSCC are similar, the multistep processes for the development and progression of both cancers overlap. However, some genetic changes seem to be unique in the biology of NPC development.
It would also be of interest to compare these allelotyping data with the allelic loss pattern of other EBV-associated neoplasias, for example post-immunosuppression/transplant, AIDS-related and Burkitt's lymphomas. However, there is only limited knowledge of LOH for comparison at present. 
